carbonic acid ethyl ester-(1-methyl-butyl ester)

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: carbonic acid ethyl ester-(1-methyl-butyl ester)
• 英文别名: Kohlensaeure-aethylester-(1-methyl-butylester)；Aethyl-(methylpropylcarbin)-carbonat；Ethyl pentan-2-yl carbonate
• 化学式: C₈H₁₆O₃
• 分子量: 160.213
• InChiKey: DIFOPVYBCNZAIF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-戊醇 、 碳酸二乙酯 在 fixed bed acidic PURALOX NWa-155 γ-alumina 作用下， 100.0~140.0 ℃ 、101.33 kPa 条件下， 生成 carbonic acid ethyl ester-(1-methyl-butyl ester)
  参考文献：
  名称：

  The Continuous Acid-Catalysed Etherification of Aliphatic Alcohols Using Stoichiometric Quantities of Dialkyl Carbonates

  摘要：

  A range of methyl and ethyl ethers of aliphatic alcohols have been synthesized cleanly in high yield by reacting the corresponding alcohol with dimethyl carbonate or diethyl carbonate over the solid acid catalyst, gamma-alumina. The reaction could be conducted at ambient pressure without the need for the large excess of dialkyl carbonate as previously reported in tie literature. If the reaction was conducted at high pressure, the conversion of the starting alcohol was greatly reduced. However, high pressure CO2 can be used as the solvent without significant reduction in yield. This has implications for tandem reactions.

  DOI：

  10.1021/op1002243

文献信息

• Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders
  申请人：Remenar Julius F.

  公开号：US20110166128A1

  公开（公告）日：2011-07-07

  The present invention provides prodrug compounds of diaryldiazepine drug compounds.

  本发明提供了二苯并二氮杂苯类药物化合物的前药化合物。
• 1-Methylcarbapenem derivatives
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20040014962A1

  公开（公告）日：2004-01-22

  1-Methylcarbapenem compounds having antibacterial activity, pharmacologically acceptable esters or salts thereof and pharmaceutical compositions (particularly antibacterial agents) containing them as an active ingredient are described. In addition, the invention includes the use of these compounds, ester derivatives or salts for the manufacture of pharmaceutical compositions, or a method for the prevention or treatment of diseases (particularly bacterial infections) by administering a pharmacologically effective amount of the compounds, ester derivatives or salts to warm-blooded animals (particularly human beings).

  描述了具有抗菌活性的1-甲基碳青霉烯化合物、它们的药物可接受的酯或盐，以及含有它们作为活性成分的药物组合物（特别是抗菌剂）。此外，发明包括这些化合物、酯衍生物或盐用于制造药物组合物，或通过向温血动物（特别是人类）投给药物有效量的这些化合物、酯衍生物或盐，用于预防或治疗疾病（特别是细菌感染）的方法。
• Prodrugs of Heteraromatic Compounds
  申请人：Alkermes Pharma Ireland Limited

  公开号：US20160009713A1

  公开（公告）日：2016-01-14

  The present invention relates to prodrugs of parent drug compounds containing heteroaromatic NH groups.

  本发明涉及含有杂芳基NH基团的母药化合物的前药。
• Antibacterial compound
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20030171330A1

  公开（公告）日：2003-09-11

  A compound of formula (I) 1 wherein R 1 and R 2 represent a hydrogen atom or an aryl, a heterocyclic, an alkyl or an alkenyl, which are optionally substituted, R 3 represents a hydrogen atom or a hydroxyl and X 1 and X 2 represent an oxygen atom, a sulfur atom or a nitrogen containing group, a pharmaceutically acceptable derivative thereof or a salt thereof. A pharmaceutical composition comprising the compound for the prevention or treatment of a bacterial infection. A method for the prevention or treatment of a bacterial infection in a warm-blooded animal comprising administering a pharmacologically effective amount of the compound.

  式（I）的化合物，其中R1和R2代表氢原子或芳基、杂环基、烷基或烯基，可以是可选择取代的；R3代表氢原子或羟基；X1和X2代表氧原子、硫原子或含氮基团，其药用上可接受的衍生物或盐。包括该化合物的药物组合物，用于预防或治疗细菌感染。一种方法，用于在温血动物中预防或治疗细菌感染，包括给予该化合物的药理有效量。
• PROCESS FOR SYNTHESIZING OXIDIZED LACTAM COMPOUNDS
  申请人：Remenar Julius F.

  公开号：US20110275803A1

  公开（公告）日：2011-11-10

  The invention provides a method for the synthesis of dehydrogenated lactam drugs of Formula I:

  本发明提供了一种合成式I去氢内酰胺类药物的方法：